1. Scrip
  2. >>Business
  3. >>Deals

Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline

New Hemophilia Partners Also Circling

 
• By Mandy Jackson

Low on cash when Pfizer handed back rights to its hemophilia A gene therapy, Sangamo is talking to partners for its Fabry disease gene therapy to fund its two lead programs through proof-of-concept.

Sangamo will sign a deal for its Fabry disease gene therapy imminently (Shutterstock)

Sangamo Therapeutics ended 2024 with only enough cash to fund its operations into the first quarter of 2025, but CEO Sandy Macrae said he is confident an imminent deal for the company’s Fabry disease gene therapy candidate, isaralgagene civaparvovec (ST-920), will fund Sangamo through human proof-of-concept for its two lead wholly-owned genetic medicine programs.

Key Takeaways
  • Sangamo expects to sign a deal soon for its Fabry disease gene therapy, the proceeds of which will fund the company's operations through clinical proof-of-concept for its two lead genetic medicine programs, now in preclinical development

The Richmond, CA-based company learned at the end of December that Pfizer planned to relinquish its rights to the partnered hemophilia A gene therapy giroctocogene fitelparvovec, which the big pharma was expected to submit for US Food and Drug Administration and European Medicines Agency approvals in early 2025, based on the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Leadership

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.